Perspectives on Outsourcing

Aug 01, 2004
BioPharm International
Technology innovations aimed at increasing yields and shortening development times can be very cost-effective, promising to reduce the need for large capital investments while getting the client into the clinic much faster.
Feb 01, 2004
BioPharm International
Current productivity initiatives may be too little, too late ? a more drastic overhaul may be required.
Jan 01, 2004
BioPharm International
By BioPharm International Editors
Biopharmaceutical companies can access their suppliers? resources to reduce validation and compliance efforts.
Dec 01, 2003
BioPharm International
Publicly traded CROs and CMOs reported solid financial results in their most recent quarter, but the big news at October's AAPS meeting was the substantial rise in new RFPs and contracts.
Nov 01, 2003
BioPharm International
As FDA tries to bring pharmaceutical manufacturing into the 21st century, changes are likely to favor companies with greater manufacturing expertise and the means to invest in new technoglogies.
Oct 01, 2003
BioPharm International
Outsourcing is in the public eye as politicians debate the lag in job growth despite a recovering economy, and the Bush Administration seeks to ?competitively source? more agency activities.
Sep 01, 2003
BioPharm International
CROs and CMOs have reported on their second quarter financial performance during July and August. Although revenues and profits were up for most companies reporting, the discussions of market conditions surrounding the financial results had a somewhat unsettled feel. Most contractors expect robust revenues in the second half of 2003 but are clearly nervous about whether the activity will actually materialize.
Aug 01, 2003
BioPharm International
BIO 2003 offered many insights into biopharma's future.
Jul 01, 2003
BioPharm International
A Dutch biotech company?s $100 million investment puts the spotlight on biomanufacturing capacity
native1_300x100
lorem ipsum